Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
A Papi, J Vestbo, L Fabbri, M Corradi, H Prunier… - The Lancet, 2018 - thelancet.com
Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
A Papi, J Vestbo, L Fabbri, M Corradi, H Prunier… - THE LANCET, 2018 - sfera.unife.it
Background: Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β2 …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
A Papi, J Vestbo, L Fabbri, M Corradi… - The …, 2018 - research.manchester.ac.uk
Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β2 …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
A Papi, J Vestbo, L Fabbri, M Corradi, H Prunier… - THE LANCET, 2018 - air.unipr.it
BACKGROUND: Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β2 …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
A Papi, J Vestbo, L Fabbri, M Corradi, H Prunier… - The Lancet, 2018 - Elsevier
Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
A Papi, J Vestbo, L Fabbri, M Corradi… - Lancet (London …, 2018 - europepmc.org
Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
[引用][C] Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group …
A Papi, J Vestbo, L Fabbri, M Corradi, H Prunier… - The Lancet, 2018 - cir.nii.ac.jp
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive
pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial | CiNii …
pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial | CiNii …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
A Papi, J Vestbo, L Fabbri, M Corradi… - The …, 2018 - portal.findresearcher.sdu.dk
Background: Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised …
A Papi, J Vestbo, L Fabbri, M Corradi, H Prunier… - 2018 - pubmed.ncbi.nlm.nih.gov
Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …